← back to search

Xinyuan Zhang

Jiangxi University of Traditional Chinese Medicine · CN
Area of research
Oncology · Pharmacology
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Drug Solubulity and Delivery Systems, Lung Cancer Treatments and Mutations, and Lung Cancer Research Studies.
h-index
44
citations
5,353
works
206
NIH funding
primary concept
email

Recent publications

Faecal metabolites as a readout of habitual diet capture dietary interactions with the gut microbiome
Nature Communications 2025cited by 4position: middledoi
Developing and Evaluating Large Language Model–Generated Emergency Medicine Handoff Notes
JAMA Network Open 2024cited by 57position: middledoi
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Clinical Cancer Research 2024cited by 27position: middledoi
HMGB2 is a biomarker associated with poor prognosis promoting radioresistance in glioma by targeting base excision repair pathway
Translational Oncology 2024cited by 8position: middledoi
Systemic immune‐inflammation index is associated with ulcerative plaque in patients with acute ischemic stroke: A single center exploratory study
Journal of Clinical Ultrasound 2023cited by 9position: middledoi
SYST-16 ANXA5 PROMOTES GLIOMA PROGRESSION THROUGH THE FAK/PI3K/AKT PATHWAY
Neuro-Oncology Advances 2023cited by 0position: firstdoi
Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective
Clinical Pharmacology & Therapeutics 2022cited by 60position: middledoi
Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2
Cell Cycle 2022cited by 7position: middledoi
Circulating Levels of the Short-Chain Fatty Acid Acetate Mediate the Effect of the Gut Microbiome on Visceral Fat
Frontiers in Microbiology 2021cited by 192position: middledoi
Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing
International Journal of Oncology 2016cited by 10position: middledoi
Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop
Oncogene 2012cited by 112position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Xiaoying Xue · Hebei Medical University2 papers (2023–2024)Cristina Menni · King's College London2 papers (2021–2025)Xuetao Han · Hebei Medical University2 papers (2023–2024)Tim D. Spector · US Forest Service2 papers (2021–2025)Panayiotis Louca · King's College London2 papers (2021–2025)Mario Falchi · St Thomas' Hospital2 papers (2021–2025)Huandi Zhou · Hebei Medical University2 papers (2023–2024)Jonathan Wolf · Defense Health Agency1 papers (2025–2025)Andrei-Florin Baleanu · King's College London1 papers (2025–2025)Pinjing Hui · Soochow University1 papers (2023–2023)Charles M. Rudin · New York Proton Center1 papers (2024–2024)Juliana Eng · Cornell University1 papers (2024–2024)Yueping Liu · Hebei Medical University1 papers (2016–2016)Matthew McCarty · Pain Management Institute1 papers (2024–2024)Rachel Gibson · King's College London1 papers (2025–2025)Wenrong Xu · Jiangsu University1 papers (2012–2012)Sarah Berry · King's College London1 papers (2025–2025)Yvonne Lau · Amgen (United States)1 papers (2024–2024)Emily R. Leeming · King's College London1 papers (2025–2025)Marina K. Baine · Michigan Medicine1 papers (2024–2024)